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Spinocerebellar ataxia type 7 (SCA7) is an inherited neurodegenerative disease that is characterised by 22 ataxia and visual loss. It results from a degeneration of cerebellar Purkinje neurons and retinal 23 photoreceptors caused by a polyglutamine repeat expansion in the ATXN7 gene, a component of the 24
STAGA transcription co-activator complex. As with many neurodegenerative diseases, studies of 25 pathogenesis have been hindered by a lack of disease-relevant models. To this end, we have generated 26 the first induced pluripotent stem cells (iPSCs) from South African SCA7 patients, where the disease 27 occurs at an unusually high frequency as a result of a founder effect. These iPSCs were capable of 28 differentiation into neural and retinal cells, and showed evidence of a transcriptional phenotype 29 affecting components of STAGA (ATXN7 and KAT2A) and the heat shock protein pathway (DNAJA1 30 and HSP70). Functionally, SCA7 iPSC-derived neurons exhibited more negative resting membrane 31 potentials and increased input resistance compared to controls, suggesting reduced excitability in 32 response to synaptic input. These results provide the first evidence of a disease phenotype in SCA7 33
iPSC-derived cells, establishing a valuable model for the study of neurodegenerative diseases and the 34 development of population-specific therapies. 35 36
Introduction 37
Spinocerebellar ataxia type 7 (SCA7) is an inherited neurodegenerative disease caused by a CAG 38 repeat expansion in the ATXN7 gene. Since the translation of this CAG repeat leads to an expanded 39 polyglutamine (polyQ) tract within the resultant protein, SCA7 is classified as a polyQ repeat disorder. 40
Other diseases with a similar pathophysiology include five different SCAs (SCA 1, 2, 3, 6 and 17), as 41 well as Huntington disease, dentatorubral-pallidoluysian atrophy and spinal bulbar muscular atrophy 42 (Orr and Zoghbi, 2007) . 43
Clinically, SCA7 patients present with ataxia, dysarthria and visual loss. This is caused by a selective 44 degeneration of cerebellar Purkinje neurons and retinal photoreceptors (Gouw et al., 1994) . Symptoms 45 progressively worsen over a period of 10 to 30 years, leading ultimately to brainstem dysfunction, 46 blindness, physical disability and death. 47
The mechanism by which a polyQ expansion within the ubiquitously expressed ATXN7 protein leads 48 to the selective degeneration of Purkinje neurons and photoreceptors remains to be fully elucidated. 49
ATXN7 is known to be a component of the mammalian transcription co-activator complex, STAGA 50 (SPT3-TAF9-ADA-GCN5 acetyltransferase) (Garden and La Spada, 2008) , and has been shown to 51 facilitate interaction between STAGA and the cone-rod homeobox (CRX) transactivator of 52 photoreceptor genes, linking the function of ATXN7 with the retinal phenotype observed in SCA7 53
patients (Palhan et al., 2005) . In neuronal cells, several studies have highlighted the role of 54 transcriptional aberrations in the dysfunction that precedes the onset of disease symptoms (Palhan et  55 As with many neurodegenerative conditions, research into the molecular pathogenesis of SCA7 has 60 been hindered by a lack of suitable models of human disease progression. This is particularly relevant 61 in cases where the genomic context of the mutation may have an impact on gene function and might 62 prove useful for therapeutic development. SCA7 occurs at an unusually high frequency in the South 63
African population as a result of a founder effect in patients of Black African ethnic origin (Smith et  64 al., 2012, Smith et al., 2016) . South African SCA7 patients also display a unique phenomenon -a 65 single nucleotide polymorphism (SNP) within ATXN7 (rs3774729), which is linked to the mutation in 66 all patients studied to date (Greenberg et al., 2006) . Approximately 43% of these individuals are 67 heterozygous for the polymorphism, allowing for allelic discrimination, and providing an ideal target 68
for developing an allele-specific silencing therapy. Recently, this haplotype has been shown to extend 69 into other Southern African populations, suggesting that such a therapy may be more widely 70 ****applicable than was first thought (Smith et al., 2015) . We have previously demonstrated the 71 efficacy of an allele-specific RNAi treatment in an over-expression cell model of SCA7 (Scholefield  72  et from all participants prior to their enrolment in the study. 97
Establishment of primary fibroblast cultures 98
Primary fibroblast cultures were established from punch skin biopsies taken from the inner forearm of 99 two unrelated SCA7 patients (P1 and P2) and an unaffected control individual (C1, sibling of P2) who 100 had consented to participate in the study, as previously described (Freshney, 2000) . CAG genotypes 101 and ages at diagnosis and biopsy are reflected in NANOG) was determined by quantitative PCR (see below). Genomic integrity was assessed by means 109 of karyotype analysis (G-banding). To confirm the iPSC lines' capacity to differentiate into the three 110 embryonic germ layers, in vitro differentiation via embryoid body formation was performed as 111 previously described (Martl et al., 2013) . 112
Neural differentiation and characterisation 113
Differentiation of iPSCs into neural precursors was performed by treatment of iPSCs with 3µM 114 glycogen synthase kinase 3 (GSK3) inhibitor (CHIR99021) and 2µM TGFβ inhibitor (SB431542) as 115 previously described (Li et al., 2011) . For neuronal differentiation, neural precursors were seeded at a 116 density of 150 000 cells/well onto a Matrigel-coated six-well plate in neural induction medium (Li et  117 al., 2011). After two days, medium was changed to neuronal differentiation medium supplemented 118 with N2, B27, 300ng/ml cyclic AMP (Sigma), 0.2mM ascorbic acid (Sigma), 10ng/ml BDNF 119 (Peprotech) and 10ng/ml GDNF (Peprotech) and cells were maintained in culture for 14 to 21 days. 120
Characterisation was performed by immunocytochemistry and qPCR (for antibodies and primers, see 121
Tables S-1.2 and S-1.3). 122
Electrophysiology 123
Neurons maintained on glass cover slips were removed from the incubator and rapidly transported to 124 the recording chamber of a Zeiss Axioskop Upright Microscope (Zeiss). Electrophysiological 125 recordings were made in neuronal differentiation medium at room temperature and were restricted to 126 the first 5 hours following cell removal from the incubator environment. Patch pipettes of 13-20 MOhm 127 tip resistance were pulled from filamental borosilicate glass capillaries (2.00 mm outer diameter, 1.58 128 mm inner diameter, Hilgenberg), using a horizontal puller (Model P-1000, Sutter). The pipettes were 129 filled with an internal solution containing (in mM): K-gluconate (126); KCl (4); Na 2 ATP (4); NaGTP 130 (0.3); Na 2 -phosphocreatinine (10) and HEPES (10). Osmolarity was adjusted to between 290 and 300 131 mOsM and the pH was adjusted to between 7.38 and 7.42 with KOH. Cells were visualised using a 132 40x water-immersion objective (Zeiss). Digital images were obtained using a CCD camera (VX55, 133 TILL Photonics). Individual cells were selected for recordings based on a small round or ovoid cell 134 body (diameters, 5-10 µm) and typically two or more extended processes. Recordings were made in 135 current clamp and voltage clamp mode using an Axopatch 200B amplifier (Molecular Devices). Data 136 acquisition was performed through an ITC-1600 board (Instrutech) connected to a PC running a 137 custom-written routine (PulseQ) under IGOR Pro (Wavemetrics). Analysis was performed using 138 custom-written scripts in MATLAB (Mathworks). 139
Retinal differentiation and characterisation 140
Differentiation into retinal photoreceptors was performed as previously described (Boucherie et al., 141 2013), using iPSCs cultured in feeder-free conditions on Matrigel in mTESR TM medium. The cells 142
were dissociated enzymatically and plated onto Matrigel-covered dishes in neural differentiation 143 medium containing N2 and B27 supplements (Life Technologies). After settling for an hour, adhered 144 cells were covered in a 2% Matrigel solution. The following day the medium was replaced with neural 145 differentiation medium without Matrigel, and cells were fed with fresh medium every second day. 146
From day 10 the medium was supplemented with 3nM recombinant SHH (R&D Systems), 50ng/µl 147 acidic fibroblast growth factor (aFGF) (R&D Systems), 10ng/µl basic fibroblast growth factor (bFGF) 148 (Miltenyi), 1mM taurine and 500nM retinoic acid (both Sigma Aldrich 
CAG repeat length determination 172
The length of the disease-causing CAG repeat in ATXN7 was determined from DNA by means of 173 polymerase chain reaction (PCR) and automated fluorescent genotyping. The PCR reaction mix 174 consisted of 0.4µM each, forward and reverse primer ( Table S- major PCR product was defined as the product generating the highest fluorescent peak, as detected 183
using the ABI 3130xl Genetic Analyzer. 184
Results 185

Generation and characterisation of iPSCs 186
Following Sendai virus-mediated reprogramming, iPSC colonies with the correct morphology (flat, 187 with distinct borders, containing tightly packed cells with a high nucleus-to-cytoplasm ratio) appeared 188 within three to four weeks (Figure 1a) . These colonies were manually picked and clonally expanded 189 in separate dishes on a feeder layer of inactivated mouse embryonic fibroblasts. Three SCA7 patient 190 iPSC lines and two control lines (representing two affected individuals and a single related, unaffected 191 control) were successfully generated and characterised (Table S-1.1).
192
Immunocytochemical analysis of SCA7 patient and control iPSC lines revealed iPSC colonies with 193 distinct nuclear staining for the pluripotency transcription factor, OCT4, compared to the surrounding 194 mouse embryonic feeder fibroblasts (Figure 1b) . The iPSC colonies also stained positive for the 195 embryonic stem cell surface marker TRA-1-60 (Figure 1b) . 196 The expression of pluripotency markers was further confirmed by qPCR. All five iPSC lines expressed 197 high levels of OCT4, SOX2 and NANOG, standard markers of pluripotency (Figure 1c ), compared to 198 donor fibroblasts or cells that had been subjected to retinal or neuronal differentiation. The expression 199 levels of SOX2 and NANOG were similar across the five iPSC lines, but lines P2b and C1b showed 200 lower levels of OCT4 expression compared to the remaining three lines (although still significantly 201 higher than differentiated fibroblasts and retinal cells). 202
Co-staining of all iPSC lines with primary antibodies against OCT4 and the nucleocapsid protein of 203 the virus (anti-NP) showed little or no evidence of NP staining in the OCT4-positive pluripotent cells 204 (Figure 1d , bottom panel), compared to intense cytoplasmic staining in newly infected fibroblasts 205 (Figure 1d , top panel). This indicated that the Sendai virus had been effectively silenced, and that the 206 iPSCs had achieved self-regulating pluripotency. All lines were assessed after passage 8. 207 208
In vitro embryoid body-mediated differentiation confirmed the ability of all five lines to differentiate 209 into the three embryonic germ layers, staining positive for forkhead box A2 (FOXA2) or alpha-210 fetoprotein (AFP) (endoderm); sarcomeric alpha actinin (ASA) or smooth muscle actin (SMA) 211 (mesoderm); and glial fibrillary acidic protein (GFAP) or βIII-tubulin (ectoderm) (Figure 1e) . 212 213
Karyotyping using standard G-banding analysis revealed no gross structural abnormalities, when iPSC 214 lines were compared to the fibroblasts from which they had been derived (Figure S-1.1) . 215
Neural differentiation of iPSCs 216 SCA7 patient and control iPSCs generated neural precursor cells (NPCs) at comparable efficiencies, 217
when cultured in neural induction medium supplemented with SB431542 (TGFβ inhibitor) and 218 CHIR99021 (GSK3 inhibitor), with 100% of the cells expressing the early neural marker Nestin, after 219 five passages (Figure 2a ). The cells also stained positive for the disease-causing protein, ATXN7 220 (Figure 2b) , and demonstrated repression of the pluripotency gene OCT4, and upregulation of the early 221 neural gene PAX6 (Figure 2c) . Therefore the spiking response of a cell to current injection can be used to determine the maturation 240 stage of a differentiating neuron: passive (least mature) → abortive spike → single spike → recurrent 241 spikes (most mature). 242
Spiking responses were collected in current-clamp mode from cells derived from four separate iPSC 243 lines: two control lines C1a (n = 42) and C1b (n = 69), and two patient lines P1a (n = 44) and P2b (n = 244 72). Although the fraction of cells which fell into each spiking response category was significantly 245 dependent on the iPSC line from which the cells were derived (p<0.0001, Chi-squared test), no trend 246 could be discerned between control and patient lines (see Figure 3e ). For example, the control line 247
C1b had the most mature phenotype with the highest fraction of cells in the single spike and recurrent 248 spiking categories whilst P2b demonstrated a relatively immature phenotype, with the majority of cells 249 displaying spiking responses falling into the passive category. However, this difference was not 250 corroborated by the other lines where the control line C1a displayed a less mature phenotype than 251 patient line P1a. The maximum number of spikes that could be elicited following current injection was 252 again significantly dependent on the cell line concerned. Mean values +/-SEM for each line were: C1a 253 0.5 +/-0.1, C1b 1.3 +/-0.2, P1a 1.0 +/-0.3 and P2b 0.4 +/-0.1 spikes, see Figure 3f , p<0.0001, 254
ANOVA. However, no consistent trend could be observed between cells derived from control versus 255 patient iPSC lines. 256
Next, we compared the resting membrane potential (Vm) of cells derived from each cell line. This 257
parameter was significantly dependent on the iPSC line from which the cells were derived (see Figure  258 3g, p = 0.0004, ANOVA). The mean resting membrane potential +/-SEM for the C1a, C1b, P1a and 259
P2b cell lines were -54.7 +/-3.1, -57.0 +/-1.7, -67.4 +/-2.8 and -67.3 +/-2.7 mV respectively. The 260
control lines had significantly more depolarised resting membrane potentials as compared to patient 261 derived cell lines (p < 0.0001, t-test). 262
We then determined the input resistance of each cell. A lower input resistance is associated with neurite 263 outgrowth and increased numbers of ion channels inserted into the plasma membrane during the 264 process of neuronal maturation. Once again, a cell's input resistance was significantly dependent on 265 the cell line to which it belonged (see Figure 3h , p = 0.0012, ANOVA). Input resistance +/-SEM was 266 4987 +/-421, 5484 +/-243, 5979 +/-513 and 7094 +/-455 mΩ for the C1a, C1b, P1a and P2b cell 267 lines respectively. Cells derived from patient lines had a significantly higher mean input resistance than 268 cells from the control lines (p = 0.0005, t-test). 269
Following our assessment of the active and passive properties of cells described above, we then directly 270 measured voltage-gated sodium and potassium currents in voltage-clamp mode (Figure 4a,b and c) . 271 As one would predict, the spiking properties of neurons are directly correlated with the size of their 272 currents. Indeed we found a significant correlation between the maximum number of spikes that could 273 be elicited in a cell and the size of its subsequently measured voltage-gated sodium and potassium 274 currents (data not shown, r = -0.62 and 0.36 for voltage-gated sodium and potassium currents 275 respectively, p < 0.0001 for both, Pearson correlation). 276
The maximum size of voltage-gated sodium currents and potassium currents measured in each cell 277 (Max. INA and Max. IK) was significantly dependent on the particular iPSC line concerned (see Figure  278 4d was no consistent trend in the size of voltage-gated currents between cells derived from control as 283 compared to iPSC lines. 284
Retinal differentiation of iPSCs 285
For the retinal differentiation of iPSCs, the Matrigel "sandwich" system facilitated a rapid self-286 organisation and differentiation of the pluripotent stem cells into structures containing cells 287 morphologically indicative of columnar neuroepithelia (Figure 5a , first image). These structures lost 288 their integrity from day 4-5, and cells spread into an adherent monolayer (Figure 5a , middle image). 289
The gradual emergence of cells with a neuronal morphology was observed from day 10 to day 30, 290 particularly in areas of low confluence (Figure 5a , last image). Following differentiation of patient 291 and control cells into retinal cells, immunocytochemical analyses were performed on cells at the end 292 of the differentiation period (day 30), to determine whether the cells expressed retinal cell markers. 293
The cells were stained for either the disease-causing protein ATXN7, or the retinal cell markers CRX 294 and RCVRN (Figure 5b) . No obvious differences in morphology were observed between SCA7 patient 295 and control-derived cells. The differentiated cells displayed varying expression levels of the retinal 296 genes CRX, PAX6, RCVRN and OTX2 (Figure 5a and c) . 297
CAG repeat length 298
In order to confirm the size of the ATXN7 CAG repeat alleles in mRNA from patient-and control-299 derived fibroblasts, iPSCs, NPCs and retinal cells, an RT-PCR-based assay was performed. The results 300
were visualised on an agarose gel (Figure S-1.2a and b) , and confirmed by automated fluorescent 301 genotyping (data not shown). The length of the CAG repeat did not appear to fluctuate during 302 reprogramming or differentiation, corresponding to previous reports in similar cell lines (Camnasio et  303 al., 2012, Koch et al., 2011) . This assay also confirmed that both the mutant and wild-type ATXN7 304 alleles were expressed by all cell types, and that there were no obvious differences in allele expression 305 in affected or unaffected cells. 306
Transcriptional dysregulation 307
To determine whether any transcriptional differences could be detected between SCA7 patient-and 308
unaffected control-derived cell types, a panel of candidate genes was selected, which had previously 309 been shown to be dysregulated in the retinal and cerebellar tissue of SCA7 mouse models and patient 310
lymphoblasts ( retinal pigment epithelium-specific protein 65kDa (RPE65). 322
No consistent, significant alterations in gene expression were observed between SCA7 patient and 323 control fibroblasts or undifferentiated iPSCs (Figure S-1.3) , highlighting the need to investigate 324 neurodegenerative phenotypes in disease-relevant differentiated cell types. 325
In contrast to the fibroblasts and undifferentiated iPSCs, several genes were found to be significantly 326 differentially expressed between SCA7 patient iPSC-derived retinal cells and NPCs, when compared 327 to the equivalent cell type derived from unaffected control lines. Two genes were consistently 328 downregulated in both retinal cells and NPCs. These included the disease-causing gene ATXN7 (p = 329 0.018, NPCs, p = 0.04, retinal photoreceptors); and the K (lysine) acetyltransferase 2A (KAT2A), 330 encoding GCN5, the histone acetyltransferase (HAT) component of the STAGA transcription 331 coactivator complex (p = 0.003, NPCs, p = 0.02, retinal photoreceptors) (Figure 6) . 332 Six genes were differentially expressed in either SCA7 patient photoreceptors or NPCs, but not both. 333
Those specific to SCA7 photoreceptors included GRIA2, encoding the glutamate receptor, ionotropic, 334 AMPA2 (GluR2) (downregulated, p = 0.04); and three retinal-specific genes, OTX2 (upregulated, p = 335 0.002), RCVRN (downregulated, p = 0.01) and RPE65 (upregulated, p = 0.001), which were not 336 assessed in NPCs. NPC-specific alterations in expression were identified in the heat shock protein 337 genes DNAJA1 (p = 0.04) and HSP70 (p = 0.04), both of which were found to be downregulated in 338 SCA7-patient derived cells. 339
Finally, BEX1, an interactor of the p75 neurotrophin receptor, which regulates neurotrophin signalling 340 and neuronal differentiation, was found to be upregulated in SCA7 photoreceptors (p=0.0006), and 341 downregulated in SCA7 NPCs (p = 0.03), indicative of a possible differential response by the different 342 cell types to the presence of mutant ATXN7. 343
As expected, a considerable degree of intra-and inter-individual variability was observed, with some 344
genes showing significant changes in gene expression in one SCA7 patient line, but not another. and control iPSCs. In addition, no obvious difference in the ability to generate GABA-positive 366 processes could be detected between SCA7 and control iPSC-derived neurons. 367
Electrophysiological studies were carried out to establish whether there were any functional differences 368 in the intrinsic properties of patient and control cells. The majority of cells recorded were capable of 369 generating spiking activity including single and multiple action potentials, an indication of neuronal 370 maturity (Moody and Bosma, 2005) . Despite the presence of significant differences in spiking 371 responses between the four cell lines, we did not observe a reliable trend between the control and 372 patient derived neurons. This is consistent with our observations of voltage-gated sodium and 373 potassium currents, which underlie spiking activity. Significant variability, perhaps due to 374 unappreciated differences in culturing conditions between cell lines, may have masked our ability to 375 detect a reliable difference in spiking responses due to mutant ATXN7. Alternatively, it may be that 376 mutant ATXN7 does not affect the spiking properties of neurons at early stages of development, 377
suggesting that an extrinsic stressor of some kind might be required to elicit a pathological phenotype. 378
Indeed, similar functional analysis of neurons derived from patients with SCA3, a related polyQ-repeat 379 disorder, showed no difference between control and patient cells until neurons were excited via bath 380 application of glutamate (Koch et al., 2011) . 381 Importantly, we did observe differences in resting membrane potential and input resistance between 382 control and SCA7 patient derived neurons. Patient cells had more negative resting membrane potentials 383 and increased input resistance compared to control cells. Both of these differences would serve to 384 reduce the excitability of neurons containing mutant ATXN7 in response to synaptic input. Reductions 385
in Purkinje cell excitability have previously been observed in animal models of SCA1 and SCA2 386 (Duvick et al., 2010 , Hansen et al., 2012 and could represent a common functional endpoint in several 387 polyQ disorders (Choppra et al., 2014) . Future work will involve exploring the underlying mechanisms 388 which might explain these differences in resting membrane potential and input resistance. Importantly, 389
it will be necessary to repeat this physiological functional analysis on iPSC derived neurons of the 390
Purkinje cell lineage in order to fully recapitulate the cerebellar-specific elements of the disease using 391 the recently published protocols (Muguruma, 2017 , Watson et al., 2018 . displayed changes in expression of these key transcripts, suggesting that these cells may serve as useful 436 models of neurodegenerative disease progression and for the testing of potential therapies (Figure 6) . The interaction between ATXN7 and CRX has been hypothesised to be a key factor behind the 451 development of retinal degeneration in SCA7 patients (La Spada et al., 2001) . Therefore the expression 452 of multiple known CRX targets, which were previously shown to be down-regulated in SCA7 mice, 453
were included in the gene expression experiments. None of these target genes (including ARR3, 454 GNAT1 or RHO) showed consistent changes in patient cells. However, transcriptional changes in the 455 expression of additional retinal genes, including OTX2 (involved in the determination of photoreceptor 456 cell fate), RCVRN (expressed in photoreceptors), and RPE65 (expressed in retinal pigment epithelial 457 cells), were noted in the patient derived cells. A significant degree of heterogeneity was observed in 458 the differentiated retinal cells, both in terms of morphology, and gene/protein expression (Figure 5) , 459 therefore additional investigation will be required to determine whether these differences can be 460 attributed to experimental differences or pathogenic mechanisms. 461 Downregulation of the HSP genes HSP70 and DNAJA1 was observed in SCA7 patient NPCs. A 462 decrease in levels of these two HSPs has been previously reported in both SCA7 mice, and human 463 patient lymphoblasts (Chou et al., 2010 , Tsai et al., 2005 . Although this decrease in expression was 464 hypothesised in mice to represent an advanced stage of disease progression, the early developmental 465
stage recapitulated by our model suggests that decreases in certain HSP genes may instead be an 466 inherent defect, which could predispose certain populations of cells to degeneration. 467
The generation of patient-specific, disease-relevant cell types is particularly important in 468 neurodegenerative diseases; as such cells provide a unique model in which to evaluate disease 469 pathogenesis without the complications associated with transgene overexpression in cell or animal 470 models. In addition, the use of cells containing the patient's own genetic background offers the 471 opportunity to investigate potential modifiers of disease onset and progression (Marsh and Thompson,  472 2006; Bilen and Bonini, 2007,) . Perhaps most importantly to the South African context, iPSC-derived 473 neurons provide the first opportunity to evaluate the efficacy of the allele-specific RNAi-based therapy 474 developed by Scholefield et al. (2009) , in disease-affected cells. 475
One significant caveat of this study remains the small number of patients assessed -a consequence of 476 the rare nature of the condition, and the challenges associated with patient recruitment in a developing 477 world setting, in which many of those affected are unable to access tertiary healthcare. Future studies 478 will focus on recruitment, in order to extend these investigations in a larger patient cohort. To control 479
for the inherent genetic variability associated with comparisons between unrelated patients, future work 480 will also focus on the generation of isogenic control lines, by means of CRISPR/Cas9-mediated 481 genome editing. 482
Nevertheless, the SCA7 iPSCs generated here serve as a resource for differentiation into a variety of 483 disease-associated cell types, providing an ideal model in which to study neurodegenerative diseases. 484
The results of this study provide the first evidence of a disease phenotype in iPSC-derived cells from 485
the South African SCA7 patient cohort, paving the way for future analysis of pathogenesis, and the 486 development of population-specific therapies. 487 Summary of SCA7 patient and unaffected control cell lines, genotypes and ages is shown in 
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